Pinus wallichiana A.B. Jacks., also known as Himalayan white pine, is recognized in traditional medicine for its various uses, including diabetes mellitus (DM). Pinus species like Pinus roxburghii (Chir pine) and Pinus gerardiana (Chilgoza pine) have shown promise for antidiabetic properties. This study focuses on the use of edible cones of Pinus wallichiana (P. wallichiana) for the potential management of DM. The methanolic extract of Pinus wallichiana (Pw.Cme) was subjected to Gas Chromatography–Mass Spectrometry (GC-MS) analysis, total phenolic content (TPC) and total flavonoid content (TFC) analyses, and qualitative phytochemical studies. The Pw.Cme and its derived fractions were evaluated for their in vitro antioxidant, α-glucosidase, α-amylase inhibitory studies, and the identified compounds were docked against enzyme targets, followed by Molecular Dynamic Simulation (MDS) studies. Detailed in vivo antidiabetic and histopathological studies were performed following standard procedures. The GC-MS analysis of Pw.Cme lead to identification of 45 compounds, and the Pinus wallichiana ethyl acetate (Pw.EtAc) fraction exhibited the highest TPC (258.55 mg gallic acid equivalent [GAE]/g) and TFC (63.05 mg quercetin equivalent [QE]/g). In 2,2-diphenyl-1-picrylhydrazyl (DPPH) and 2,2’-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid (ABTS) assays, the respective highest anti-radical activity was observed for Pw.EtAc, as IC50=13.0 µg/mL and 5.3 µg/mL. In enzymes inhibition studies, considerable α-amylase inhibition was observed for Pw.EtAc with IC50=1.98 µg/mL, and IC50=7.2 µg/mL for α-glucosidase. In vivo studies indicated that the administration of Pw.EtAc resulted in a marked decrease in fasting blood glucose levels, hyperlipidemia, and weight loss in diabetic albino mice. Histopathology of vital organs of albino mice, administered with various doses of Pw.EtAc showed a healing effect against alloxan-induced lesions in the heart, pancreas, liver, and kidneys. In conclusion, we can claim that the extract of P. wallichiana cones is rich in many phytocomponents and have potential antidiabetic properties.

Jurinea himalaica, a medicinal plant native to the Western Himalayas, was comprehensively studied for its phytochemical composition and pharmacological potentials. Qualitative phytochemical studies, polarity directed extraction of various fractions, and column chromatography based isolation of compounds were performed. Crude samples including crude methanolic extract (Jh.Cme), n-hexane (Jh.Hex), and chloroform (Jh.Chf) were tested against acetylcholinesterase (AChE), butyrylcholinesterase (BChE), and urease enzymes. Samples were also tested for their free radicals scavenging potentials using 2,2-diphenyl-1-picrylhydrazyl (DPPH), 2,2′-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) (ABTS), and hydrogen peroxide (H2O2) assays. The antimicrobial potentials of the crude samples were appraised against bacterial and fungal strains, and phytotoxic studies were also performed following standard procedures. Qualitative phytochemical studies identified the presence of alkaloids, flavonoids, terpenoids, glycosides, saponins, and anthraquinones with terpenoids found in particularly high abundance. Column chromatographic separation led to tentative identification of a bioactive compound. The Jh.Chf was found highly potent and inhibited considerable AChE and BChE inhibitory potentials with IC50 values of 85 and 43 μg/mL, respectively. Notably, the Jh.Chf showed strong urease inhibitory activity (IC50 = 63 μg mL−1) which was comparable to the control drug thiourea. The Jh.Chf revealed considerable radical scavenging potentials against DPPH, ABTS and H2O2 radicals with IC50 values of 30, 25, and 19 μg mL−1, respectively. The tested samples also revealed gastroprotective potentials by inhibition of urease enzyme and inhibition of Proteus mirabilis with a diameter of inhibitory zone (DIZ) of 22.8 mm. A considerable antibacterial activity against Escherichia coli (MIC 0.91 mg mL−1) and strong antifungal potentials against Aspergillus flavus with minimum fungicidal concentrations (MFCc) as low as 1.11 µg mL−1 signify its potential antimicrobial effects. The phytotoxic assay also demonstrated that Jh.Cme and Jh.Chf significantly suppressed radish seed germination (up to 88

Naringin (NR) has been recognized as a potent flavonoid having notable antioxidant, anti-inflammatory, and anti-cancer properties. The unusual physicochemical properties of NR, such as poor water solubility, limit its therapeutic efficacy despite its pharmacological significance. Because of its natural antioxidant and anticancer properties, lecithin is considered a safe surfactant. It is being hypothesized that biotin-conjugated carriers could enhance the uptake of anticancer drugs by tumor cells, making them effective in tumor-targeting. In this study, amphiphilic biotin (ABT) was synthesized and incorporated into a lecithin-based SNEEDS to improve the anticancer and antioxidant properties of NR. Solubility of NR in different oils, surfactants, and co-surfactants was assessed to select the best constituents for the SNEDDS formulation. A ternary phase diagram for choosing formulation composition was produced based on droplet size, zeta potential, and emulsification studies. The formulation primarily consists of lipid (cinnamon oil), surfactants (Tween 60 + Lecithin), and a co-surfactant (Transcutol). Optimized formulations were characterized using FTIR, DLS, and AFM. These formulations were further evaluated for thermodynamic stability and dilution. The results showed that the mean droplet size and zeta potential for ABT-incorporated NR-SNEDDS were 128.17 ± 19.11 nm and − 21.4 ± 1.53 mV, whereas for NR-SNEDDS were 116.47 ± 19.12 nm and − 32.5 ± 2.19 mV, respectively. Antioxidant and anticancer properties of NR were significantly enhanced by incorporating it into the ABT-modified SNEDDS, according to the findings. The results suggest that incorporating novel Lecithin containing ABT functionalized NR-loaded SNEDDS can significantly improve the anticancer and antioxidant capabilities of NR. ABT-modified lecithin-based SNEDDS is an effective carrier system for enhancing the therapeutic efficacy of NR. The incorporation of ABT into the NR-SNEDDS significantly enhanced the antioxidant and anticancer properties of NR. The ABT-modified NR-SNEDDS formulation achieved a droplet size of 128.17 ± 19.11 nm and a zeta potential of -21.4 ± 1.53 mV, reflecting improved stability. ABT was successfully synthesized and incorporated into a lecithin-based SNEDDS to enhance the delivery and efficacy of NR.

BACKGROUND:Alzheimer's disease (AD) is a neurological disorder characterized by cognitive decline and behavioral distrubance which are expected to significantly affect the patient's quality of life. Previous studies revealed the neuroprotective effects of progesterone. Furthermore, the aim of this study was to assess the neuroprotective potentials of new derivatives of progesterone (AN-1 to AN-5). METHODS:Following compound synthesis and structure elucidation, in vitro antioxidant (DPPH), acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) inhibitory activities, as well as molecular docking studies, were performed, according to the standard procedures and the most potent compound was then subjected to more detailed behavioral studies, including the Y-Maze, Elevated Plus Maze (EPM), and open field tests in scopolamine-induced amnesic animals. RESULTS:In the DPPH assay, the AN-1 compound at 1000 μg/ml concentration exhibited 83.37 ± 2.03% inhibition of DPPH free radicals with an IC50 value of 57.21 μM. Likewise, the compound AN-1 demonstrated 88.94 ± 1.20% inhibition against AChE and 86.78 ± 1.24% inhibition against BChE enzymes at 1000 μg/ml with IC50 values of 56.52 and 43.33 μM, correspondingly. In behavioral studies, compound AN-1 demonstrated a significant decline in cognitive impairments and improved working memory as well as locomotor activities of the amnesic animals. Molecular docking studies also demonstrated that the compound AN-1 has promising inhibitory potentials against AChE and BChE enzymes by binding to their active site amino acid residues. The binding energies of AN-1 with both enzymes were -7.6 Kcal/mol for AChE and -8.1 Kcal/mol for BChE. CONCLUSION:Based on our findings, it is concluded that the derivatives of progesterone exhibit neuroprotective potential, and further research is needed to extend their neuroprotective role in the treatment of AD.

There was an error in the original publication [...]

AIM:Schiff bases, owing to their versatile pharmacological and industrial applications, have attracted significant attention in drug design. MATERIAL AND METHODS:The newly synthesized Schiff Base derivatives of bromhexine were characterized using spectral techniques, including Infrared (IR), Nuclear Magnetic Resonance (1 H NMR, 13C NMR) analyses. Pharmacokinetic studies via SwissADME web server. Antiviral screening using the hemagglutination inhibition assay identified BM9 as the most potent compound (IC50 = 3.01 ± 1.70). Antioxidant activity was assessed using the DPPH method. RESULTS AND CONCLUSION:Molecular docking studies against α-amylase and α-glucosidase revealed strong inhibition scores, with BM6 and BM7 emerging as the most promising candidates. This study concludes that derivatives could serve as lead compounds in the development of novel therapeutic agents.

Aim: Breast cancer is the most recurring cancer among females and is being diagnosed as a major cause of death among women.Materials & methods: Levosulpiride Schiff base derivatives were synthesized and analyzed by physical and spectral (FTIR, 1H-NMR, 13C-NMR) analysis. MTT assay against MCF-7 (human breast cancer cell line), scavenging activity and Molecular docking against receptors 1M17, 3PP0, 3IOK and 4KIK along ADME pharmacokinetic studies were performed.Results & conclusion: L1 and L3 synthesized derivatives have revealed better percent cell viability and inhibitory concentration (IC50) with scavenging activity as of the parent compound. L1, L3 and L9 revealed significant docking scores compared with standard drugs. Most of the derivatives showed strong pharmacokinetic profiles while no drug crossed blood-brain barrier. The newly synthesized L1 and L3 levosulpiride-derived compounds have demonstrated promising anticancer properties against breast cancer cells.

Background: Alzheimer's diseases (AD) and dementia are among the highly prevalent neurological disorders characterized by deposition of beta amyloid (A beta) plaques, dense deposits of highly phosphorylated tau proteins, insufficiency of acetylcholine (ACh) and imbalance in glutamatergic system. Patients typically experience cognitive, behavioral alterations and are unable to perform their routine activities. Evidence also suggests that inflammatory processes including excessive microglia activation, high expression of inflammatory cytokines and release of free radicals. Thus, targeting inflammatory pathways beside other targets might be the key factors to control- disease symptoms and progression. Purpose: This review is aimed to highlight the mechanisms and pathways involved in the neuroprotective potentials of lead phytochemicals. Further to provide updates regarding challenges associated with their use and their progress into clinical trials as potential lead compounds. Methods: Most recent scientific literature on pre-clinical and clinical data published in quality journals especially on the lead phytochemicals including curcumin, catechins, quercetin, resveratrol, genistein and apigenin was collected using SciFinder, PubMed, Google Scholar, Web of Science, JSTOR, EBSCO, Scopus and other related web sources. Results: Literature review indicated that the drug discovery against AD is insufficient and only few drugs are clinically approved which have limited efficacy. Among the therapeutic options, natural products have got tremendous attraction owing to their molecular diversity, their safety and efficacy. Research suggest that natural products can delay the disease onset, reduce its progression and regenerate the damage via their anti-amyloid, anti-inflammatory and antioxidant potentials. These agents regulate the pathways involved in the release of neurotrophins which are implicated in neuronal survival and function. Highly potential lead phytochemicals including curcumin, catechins, quercetin, resveratrol, genistein and apigenin regulate neuroprotective signaling pathways implicated in neurotrophins-mediated activation of tropomyosin receptor kinase (Trk) and p75 neurotrophins receptor (p75NTR) family receptors. Conclusions: Phytochemicals especially phenolic compounds were identified as highly potential molecules which ameliorate oxidative stress induced neurodegeneration, reduce A beta load and inhibit vital enzymes. Yet their clinical efficacy and bioavailability are the major challenges which need further interventions for more effective therapeutic outcomes.

Background/Objectives: Inflammation and analgesia are two prominent symptoms and often lead to chronic medical conditions. To control inflammation and analgesia, many marketed drugs are in practice but the majority of them have severe side effects. Methods: This study involved the synthesis of a pivalate-based Michael product and evaluated it for in vitro COX-1, COX-2, and 5-LOX inhibitory potentials using specific assays. Molecular docking studies were also assessed. Based on the in vitro results, the compound was also subjected to in vivo anti-inflammatory and antinociceptive studies. Results: The pivalate-based Michael product (MAK01) was synthesized by an organocatalytic asymmetric Michael addition of ethyl isobutyrate to N-phenylmaleimide with an isolated yield of 96%. The structure of the compound was confirmed through 1H and 13C NMR analyses. The observed IC50 values for COX-1, COX-2, and 5-LOX were 314, 130, and 105 μg/mL, respectively. The molecular docking studies on the synthesized compound showed binding interactions with the minimized pockets of the respective enzymes. In a carrageenan model, a percent reduction in edema when administered at 10 mg/kg (a reduction of 33.3 ± 0.77% at the second hour), 20 mg/kg (a reduction of 34.7 ± 0.74% at the second hour), and 30 mg/kg (a reduction of 40.58% ± 0.84% after the fifth hour) was observed. The compound showed a significant response at concentrations of 50, 100, and 150 mg/kg with latency times of 10.32 ± 0.82, 12.16 ± 0.51, and 12.93 ± 0.45 s, respectively. Conclusion: In this study, we synthesized a pivalate-based Michael product for the first time. Moreover, based on its rationality and potency, it was found to be an effective future medicine for the management of analgesia and inflammation.

Background: Derivatization has been tremendously utilized in the field of drug discovery for optimizing the pharmacological properties and improving safety, efficacy and selectivity. Methodology: Schiff's bases (AD1-AD11) are synthesized through amantadine condensation with different aldehydes and ketones. Fourier transform infrared, H-1 NMR, C-13 NMR, TLC, liquid chromatography mass spectrometry analysis, in silico studies, molecular docking and antiviral activity through hemagglutinin test were performed for evaluation of new compounds. Results: AD2, 3 and 9-11 showed greater antiviral activity than the parent drug. Among all derivatives, AD2 and AD3 exhibited good potential against alpha-amylase while AD7 and AD10 showed stronger inhibition against alpha-glucosidase. Conclusion: So, it is concluded that the most potent derivatives can be used as lead compounds in novel drug design of antiviral antidiabetic agents.

Herein we described the biofabrication of samarium oxide nanoparticles (HT-Sm2O3 NPs) by applying the aqueous fruit extract of Hyphaene thebaica was utilized as an eco-friendly chelating agent. The prepared NPs were subjected to various physicochemical properties and potential in biomedical applications. X-ray Diffraction (XRD) pattern revealed sharp peaks that corroborated with the Joint Committee on Powder Diffraction Standards (JCPDS) card no. 00-042-1464. Crystallite size obtained from Debye-Scherrer approximation and Williamson-Hall (W-H) plot was 28.73 and 69.3 nm, respectively. Optical bandgap was calculated by employing Kubelka-Munk (K-M) function and was found to be similar to 4.58 eV. Raman shift was observed at 121, 351, 424(-), and 561 cm(-1). Photoluminescence (PL) spectra revealed two major peaks positioned at 360 and 540 nm. The high-resolution transmission electron microscopy (HR-TEM) analysis of HT-Sm2O3 nanoparticles (NPs) showed that they predominantly have spherical to cuboidal shapes. Additionally, the selected area electron diffraction (SAED) pattern presented spotty rings, indicating a high level of crystallinity in these NPs. The potential nanomedicine applications were studied using diverse bioassays using different treatments. The antioxidant activity demonstrated 45.71% +/- 1.13% inhibition at 1000 mu g/mL. Brine shrimp lethality assay revealed the highest cytotoxicity of 46.67% +/- 3.33% at 1000 mu g/mL and LC50 value of 1081 mu g/mL. HT-Sm2O3 NPs exhibited inhibition of angiogenesis (20.41% +/- 1.18%) at of 1000 mu g/mL. MTT assay results indicated that HT-Sm2O3 NPs exhibit inhibitory effects on cell lines. Specifically, these NPs showed an IC50 value of 104.6 mu g/mL against 3T3 cells. Against MCF-7 cells, the NPs demonstrated an IC50 value of 413.25 mu g/mL. Additionally, in the inhibition of acetylcholinesterase (AChE), the newly synthesized NPs showed an IC50 value of 320 mu g/mL. The antidiabetic assessment through alpha-glucosidase and alpha-amylase inhibition assays revealed, an IC50 value of 380 mu g/mL for alpha-glucosidase and 952 mu g/mL for alpha-amylase was calculated. Overall, our study suggested that the Sm2O3 NPs possess moderate anticancer, cholinesterase inhibition, and antidiabetic potential, however, needs further assessment. Research Highlights In this work, nano-samaria is synthesized using an eco-friendly and green approach. The nanoparticles were characterized using techniques such as Raman, HR-TEM, FTIR, DRS, XRD, and so on, and the applications were studied using multiple in vitro bioassays for Diabetes, Alzheimer, and Cancer. The nano-samaria revealed good potential for potential biomedical applications.

Background: Quercetin being antioxidant and antiproliferative agent acts by inhibiting CDK2, with an increase in cancer prevalence there is a need to profile quercetin derivatives as CDK2 inhibitors. Materials & method: Schiff bases of quercetin were synthesized as cytotoxic agents against the MCF7 cell line. FTIR, H-1-NMR and C-13-NMR, CHNS/O analysis were employed along with in vivo and in silico activities. Results & conclusion: 2q, 4q, 8q and 9q derivatives have maximum cytotoxic effect with IC50 values 39.7 +/- 0.7, 36.65 +/- 0.25, 35.49 +/- 0.21 and 36.99 +/- 0.45, respectively. Molecular docking also confirmed these results 8q has the highest binding potential of -9.165 KJ/mole making it a potent inhibitor of CDK2. These derivatives can be used as lead compounds as potent CDK2 inhibitors.

AIMS:This study focuses on the synthesis and characterization of novel sitagliptin derivatives, aiming to develop potent, orally active anti-diabetic agents with minimal side effects for the management of type 2 diabetes mellitus. Copper (II) (SCu1-SCu9) and zinc (II) (SZn1-SZn9) metal complexes of sitagliptin-based derivatives were synthesized via a template reaction. MATERIAL & METHOD:The synthesized complexes were comprehensively characterized using elemental analysis, FTIR, UV-Vis, 1 h NMR, and 13C NMR spectroscopy. The biological efficacy of these compounds was assessed through α-amylase and α-glucosidase enzyme inhibition assays, with molecular simulation studies providing additional confirmation of their inhibitory activity. RESULTS:Among the tested derivatives, SD7, SD4, SD3, SD5, and SD9 demonstrated enzyme inhibition profiles comparable to the standard inhibitors. However, the metal complexes exhibited absorption challenges, which may influence their bioavailability. CONCLUSION:These findings highlight the significant anti-diabetic potential of the synthesized compounds against targeted enzymes, establishing a foundation for their development as lead molecules in future therapeutic research.

Aim: Calcium channel antagonists are of considerable interest in treating elevated blood pressure and its pathologies. Materials & methods: Schiff base derivatives of amlodipine were produced to check its urease inhibition potentials as well antibacterial and antioxidant activities. Structural illustration along with chemical characterization were achieved by spectral techniques (1H NMR, FTIR, 13C NMR) and docking studies also performed. Results & conclusion: 3g displayed remarkable anti-hypertensive activity compared with parent drug. 3b, 3f and 3g showed urease inhibition potentials. These compounds can aid as lead for further investigations since they exhibited comparable or superior interactions.

In recent times, the field of nanomedicine has shown great promise, offering significant advancements in diagnostic and treatment methods, especially with the use of nanomaterials. By integrating nanomaterials with imaging, the detection capabilities for GI tumors and inflammatory bowel disease have been greatly enhanced. This powerful combination enables early diagnosis and precise staging of GI disorders, leading to better patient outcomes. Various strategies have been developed to improve the therapeutic effectiveness and targeting of nanomaterials. Through innovative nanoparticle vectors, drugs can be delivered precisely to the affected areas in the GI tract, ensuring prolonged and localized treatment, thereby minimizing unwanted side effects. In this chapter, we explored the various possibilities of utilizing nanomaterials for diagnosing and treating GI disorders.

Diabetes mellitus (DM) is a metabolic disorder majorly arising from the pathophysiology of the pancreas manifested as a decline in the insulin production or the tissue’s resistance to the insulin. In this research, we have rationally designed and synthesized new succinimide–thiazolidinedione hybrids for the management of DM. In a multistep reaction, we were able to synthesize five new derivatives (10a–e). All the compounds were new containing a different substitution pattern on the N-atom of the succinimide ring. Initially, all the compounds were tested against the in vitro α-glucosidase, α-amylase, PTP1B, and DPP4 targets. In all of these targets, the compound 10d was observed to be the most potential antidiabetic agent. Based on this, the antidiabetic activity of the compound 10d was further investigated in experimental animals, which overall gave us encouraging results. The molecular docking studies of the compound 10d was also performed against the target enzymes α-glucosidase, α-amylase, PTP1B, and DPP4 using MOE. Overall, we observed that we have explored a new class of compounds as potential antidiabetic agents.

The current research reports the synthesis of 14 para-substituted thiosemicarbazone derivatives in good to excellent yields using standard procedures. Initially, 4-ethoxybenzaldehyde (1) and 4-nitrobenzaldehyde (2) were refluxed with thiosemicarbazide in the presence of acetic acid in ethanol for 4-5 h. Then, various substituted phenacyl bromides were treated with the desired thiosemicarbazones (3 and 4) in the presence of triethylamine in ethanol with constant stirring for 5-6 h. The resulting derivatives were confirmed through electron impact mass spectrometry and 1H NMR spectroscopy and evaluated for anticholinesterase inhibitory activity. Among the series, four compounds, 19, 17, 7, and 6, showed potent inhibitory activity against the acetylcholinesterase (AChE) enzyme, having IC50 values of 110.19 ± 2.32, 114.57 ± 0.15, 140.52 ± 0.11, and 160.04 ± 0.02 μM, respectively, compared with standard galantamine (IC50 = 104.5 ± 1.20 μM). Similarly, compounds 19 (IC50 = 145.11 ± 1.03 μM), 9 (IC50 = 147.20 ± 0.09 μM), 17 (IC50 = 150.36 ± 0.18 μM), and 6 (IC50 = 190.21 ± 0.13 μM) were the most excellent inhibitors of butyrylcholinesterase (BChE) when compared with the standard drug galantamine (IC50 = 156.8 ± 1.50 μM). In silico studies were accomplished on the produced derivatives in order to explain the binding interface of compounds with the active sites of AChE and BChE enzymes.

This study aimed to evaluate 2-(N-((2′-(2H-tetrazole-5-yl)-[1,1′-biphenyl]-4yl)-methyl)-pentanamido)-3-methyl butanoic acid-based ester derivatives as a new class of angiotensin-II receptor antagonists. For this purpose, a series of compounds were synthesized using a variety of phenols. Their chemical characterization was established by FTIR, 1HNMR, and 13CNMR techniques. The biological activities including antioxidant potentials using the DPPH assay, the antihypertensive assay, the urease enzyme inhibition assay, and the antibacterial assay using agar well diffusion methods were performed. All the new compounds showed significant free radical scavenging potentials more than the parent drug while retaining antihypertensive potentials along with urease inhibition properties. However, the AV2 test compound was found to be the most potent against hypertension. Most of the synthesized analogs showed urease inhibitory actions. Molecular docking studies were performed for all the active analogs to decode the binding detail of the ligands with receptors of the enzyme’s active site.

Phytoextracts modulated synthesis of nano‐scaled spherical lanthanum oxide nanoparticles (La2O3 NPs) are reported using the aqueous extracts of Hyphaene thebaica as a bioreducing and chelating agent. X‐ray diffraction (XRD) pattern revealed sharp peaks and single‐phase purity. The Debye–Scherrer approximation indicated an average crystallite size of 37 nm, whereas W‐H plot revealed a crystallite size of 59 nm, complemented by the high‐resolution transmission electron microscopy (HR‐TEM). The infrared spectroscopy revealed characteristic La‐O band at 426 and 648 cm−1. K‐M function revealed the bandgap of 5.6 eV, whereas broad intense emission peaks between 345 and 750 nm. The Raman spectra revealed peaks at 182, 325, 384, and 491 cm−1. Elemental composition was confirmed using energy‐dispersive X‐ray spectroscopy (EDS) spectrum, and the spotty rings from selected area electron diffraction (SAED) indicated the crystalline nature of the HT‐La2O3 NPs. In addition, the HT‐La2O3 NPs were investigated for in vitro antioxidant, anticancer, antiangiogenic, and cytotoxic potentials. DPPH free radical scavenging activity was highest, that is, 49.54 ± 0.88% at 1000 μg/mL. MTT assay on MCF‐7 and 3T3 cell lines revealed a median lethal concentration of 114 and 43 μg/mL, respectively. The antiangiogenic effect examined by chick chorioallantoic membrane (CAM) assay indicated inhibition of 57.14 ± 0.96% at 1000‐μg/mL concentration with an IC50 of 551 μg/mL. IC50 for the brine shrimp lethality assay was 314.2 μg/mL. Our study indicates cytotoxicity of HT‐La2O3 NPs, and it further concluded that HT‐La2O3 NPs were more potent against 3T3 cells as compared with MCF‐7 cells. Further research on the biological synthesis and anticancer studies are recommended for the large‐scale applications of the La2O3 NPs.